Kansas City - New Vaccine Surveillance Network (KC-NVSN)

项目摘要： 堪萨斯市-新疫苗监测网络（KC-NVSN）计划于2009年建立， 对儿童急性胃肠炎（AGE）疾病进行基于人群的、实验室确认的主动监测 在密苏里州堪萨斯城的儿童慈善医院寻求治疗。该计划随后扩大 2015年，将住院的ARI儿童纳入住院（IP）环境。 在目前的提案中，KC-NVSN计划旨在继续现有的儿科AGE IP和门诊 (OP)六个县KC大都市区的监测和杰克逊县的ARI IP监测，MO。在 此外，我们将扩大ARI监测范围，从杰克逊县到主要CMH紧急情况的OP 部门年龄和时间匹配的健康对照儿童也将入组。符合资格的儿童到访或 将使用批准的许可和同意表入组上述医院系统 CMH的机构审查委员会（IRB）。我们会进行家长访谈，收集病历数据 并检索登记儿童的流感和轮状病毒疫苗信息的硬拷贝。临床 从儿童采集的标本将进行轮状病毒（和其他胃肠道病原体，如诺如病毒， 和22种来自呼吸道标本的呼吸道病原体， 流感亚型和其他非流感病毒，如RSV，EV-D 68等。 KC-NVSN计划将提供基于人口的估计，以实现以下具体目标： 1.评估疫苗预防轮状病毒和流感的有效性 通过试验阴性病例对照研究设计，使用实验室确认的检测， 登记的儿童。 2.评估选定AGE病原体和非流感病毒病原体的负担，包括 呼吸道合胞病毒和EV-D 68。 KC-NVSN计划将提供与其他地理位置不同的站点相结合的数据，以估计 社区获得性AGE和ARI的全国发病率、负担和病因。轮状病毒的VE和 将计算季节性流感疫苗接种情况，以衡量疫苗接种的影响。该网络还将 解决与儿科感染性疾病自然史相关的几个重要科学问题， 传播动态、疫苗对目标人群和脆弱人群的影响以及影响 疫苗有效性。从这个网络产生的监测数据将提供及时和非常有用的 为旨在控制AGE和ARI的公共卫生措施和儿科疫苗相关政策提供信息的数据 在美国儿童。

Project Summary: The Kansas City-New Vaccine Surveillance Network (KC-NVSN) program was established in 2009 to conduct population-based, laboratory-confirmed, active surveillance of acute gastroenteritis (AGE) illness in children seeking care at Children's Mercy Hospital, in Kansas City (KC), MO. The program was subsequently expanded in 2015 to include hospitalized ARI children in inpatient (IP) settings. In the current proposal, the KC-NVSN program seeks to continue the existing pediatric AGE IP and outpatient (OP) surveillance in the six county KC metropolitan area and ARI IP surveillance in Jackson County, MO. In addition, we will expand ARI surveillance to OP from Jackson County visiting the main CMH emergency department. Age and time matched healthy control children will also be enrolled. Eligible children visiting or admitted to our hospital system as defined above will be enrolled using permission and assent forms approved by the institutional review board (IRB) of CMH. We will conduct parent interviews, collect medical chart data and retrieve hard copies of vaccine information for influenza and rotavirus from enrolled children. Clinical specimens collected from children will be tested for rotavirus (and other GI pathogens, e.g. norovirus in proposed subprojects) in stool and 22 respiratory pathogens from respiratory specimen including specific influenza subtypes and other non-influenza viruses, such as RSV, EV-D68 etc. The data collected from the KC-NVSN program will provide population-based estimates to address the following specific aims: 1. To assess vaccine effectiveness (VE) in preventing medically attended rotavirus and influenza illness by the test-negative case-control study design using laboratory confirmed testing among enrolled children. 2. To assess the burden of select AGE pathogens and non-influenza viral pathogens, including respiratory syncytial virus and EV-D68 among enrolled children. The KC-NVSN program will provide data to be combined with other geographically diverse sites to estimate the national incidence, burden, and etiology of community-acquired AGE and ARI. The VE for rotavirus and seasonal influenza vaccinations will be calculated to measure the impact of vaccination. This network will also address several important scientific questions related to natural history of pediatric infectious diseases, transmission dynamics, impact of vaccine on targeted and vulnerable population and factors that influence vaccine effectiveness. The surveillance data generated from this network will provide timely and highly useful data to inform public health measures and pediatric vaccine-related policies aimed at controlling AGE and ARI in US children.